SELECTION OF A CRYOPROTECTOR FOR PRODUCTION A LYOPHILIZED LIPOSOMAL DOSAGE FORM OF THE INDOLOCARBAZOLE DERIVATIVE LHS‑1269

Introduction. One of the key tasks in freeze‑drying of drug is to choose the optimal cryoprotector that provides a high‑quality lyophilized product.

The aim of research. Selection of cryoprotectant and its concentration for the preparation of lyophilizate of the liposomal dosage form of the indolocarbazole derivative LHS‑1269.

Materials and methods. Substance LHS‑1269 ≥99 % (N. N. Blokhin National Medical Research Center of Onco logy), egg phosphatidylcholine Е РС S (Lipoid, Germany), cholesterol ≥99 % (Sigma‑Aldrich, Japan), polyethylene glycol‑2000‑distearoyl phosphatidylethanolamine (Lipoid, Germany), mannose‑d (+) 99 % (Kaden, Germany), sucrose (Himmed, Russia), trehalose dihydrate (Himmed, Russia). To obtain LHS‑1269 liposomes, the Bangham method was used in modification for hydrophobic substances with subsequent extrusion of the dispersion of multilayer phos‑ pholipid vesicles. The prepared liposomal dispersion was dosed into vials of 6 ml and lyophilized in the freeze‑dryng chamber using the «step‑by‑step» freezing mode. LHS‑1269 liposomes were analyzed before and after freeze‑drying using laser scattering spectroscopy and determination of the electrophoretic mobility of particles.

Results. To prevent the destruction of LHS‑1269 liposomes during lyophilization, substances from the carbohy‑ drates class – mannose, sucrose and trehalose – were studied in two concentrations. In the course of compara‑ tive evaluation of the obtained lyophilizates in terms of quality, appearance, rehydration, size and zeta potential of liposomes before and after sublimation, it was found that sucrose introduced into the liposomal dosage form LHS‑1269 in the molar ratio sucrose / egg phosphatidylcholine 5:1 has optimal cryoprotective properties.

Conclusion. As a result of the study, the optimal cryoprotector and its concentration were selected, which ensure the production of high‑quality lyophilizate of the liposomal composition of the indolocarbazole derivative LHS‑1269. 

1. Kasper J.C., Winter G., Friess W. Recent advances and further challenges in lyophilization. Eur J Pharm Biopharm 2013;85(2):162–9. DOI: 10.1016/j.ejpb.2013.05.019.

2. Wang Y., Grainger D.W. Lyophilized liposome-based parenteral drug development: reviewing complex product design strategies and current regulatory environments. Adv Drug Deliv Rev 2019;151–152:56–71. DOI: 10.1016/j.addr.2019.03.003.

3. Ghanbarzadeh S., Valizadeh H., ZakeriMilani P. The effects of lyophilization on the physico-chemical stability of sirolimus liposomes. Adv Pharm Bull 2013;3(1):25–9. DOI: 10.5681/apb.2013.005.

4. Shanskaya A.I., Puchkov S.M., Chmielova G.A., Neudachina N.A. Liposomal drug Lipoferum for intravenous administration with alpha-tocopherol. Actualniye voprosi transfuziologii i klinicheskoy meditsini = Topical issues of Transfusiology and clinical medicine 2015;1:156–8. (In Russ.).

5. Kostyaev A.A., Utemov S.V., Andreev A.A. et al. Annals of Cryobiology. Classification of cryoprotectors and cryopreservants for blood cells and bone marrow. Vestnik gematologii = Bulletin of Hematology 2016;12(3):23–7. (In Russ.).

6. Izutsu K.I. Applications of freezing and freeze-drying in pharmaceutical formulations. Adv Exp Med Biol 2018;1081:371–83. DOI: 10.1007/978-981-13-1244-1_20.

7. Guimarães D., Noro J., Silva C. et al. Protective effect of saccharides on freeze-dried liposomes encapsulating drugs. Front Bioeng Biotechnol 2019;7:424. DOI: 10.3389/fbioe.2019.00424. 8. Li J., Hu M., Xu H. et al. Influence of type and proportion of lyoprotectants on lyophilized ginsenoside Rg3 liposomes. J Pharm Pharmacol 2016;68(1):1–13. DOI: 10.1111/jphp.12489.

8. Lugen B., Dmitrieva M.V., Orlova O.L. et al. Development of a liposomal dosage form based on hydrophobic derivative of indolocarbazole. Razrabotka i registratsiya lekarstvennykh sredstv = Drug development & registration 2020;9(3):21–6. (In Russ.).